Jingzhou Central Hospital
Jingzhou Central Hospital
Jingzhou, Hubei, China14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | Prurigo Nodularis (PN) | Recruiting | Phase 2 | 2026-09-14 | NCT07236099 | |
| ASPIrin in Reducing Events in Dialysis ( ASPIRED ) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 4 | 2026-09-14 | NCT04381143 | |
| A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Recruiting | Phase 3 | 2026-09-09 | NCT07724366 | |
| Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC | renal pelvis/ureter urothelial carcinoma | Recruiting | Phase 2 | 2026-08-03 | NCT07741448 | |
| Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC | MIBC | Recruiting | Phase 3 | 2026-07-09 | NCT07693959 | |
| A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 2 | 2026-07-08 | NCT07509892 | |
| Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study | Skin and Connective Tissue Diseases, connective tissue disorder, cutaneous lupus erythematosus, skin disorder | Recruiting | Phase 2 | 2026-06-08 | NCT07440537 | |
| Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT. | DNA Virus Infections, Herpesviridae infectious disease, Infections, cytomegalovirus infection, graft versus host disease, immune system disorder, viral infectious disease | Recruiting | Phase 4 | 2026-06-01 | NCT07569653 | |
| Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Phase 2 / Phase 3 | 2026-04-21 | NCT07378527 | |
| Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis Patients | Recruiting | Phase 3 | 2026-02-09 | NCT06842199 | |
| ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 3 | 2025-09-08 | NCT06775860 | |
| ICP-332 in Subjects With Non-segmental Vitiligo | Non Segmental Vitiligo | Recruiting | Phase 2 / Phase 3 | 2025-08-07 | NCT07047612 | |
| MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2024-04-10 | NCT06345365 | |
| Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System | cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Not yet recruiting | Not applicable | 2021-08-06 | NCT04995159 |